SimplePractice vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
All-in-one practice management platform for 185,000+ therapists, counselors, social workers, and wellness practitioners; Santa Monica-based;
About
SimplePractice is a Santa Monica-based practice management software company serving independent therapists, counselors, social workers, nutritionists, and other health and wellness practitioners. The platform provides scheduling, client intake forms, HIPAA-compliant telehealth video sessions, insurance billing, payment processing, progress notes, and client messaging in a unified system designed specifically for solo and small group private practices. SimplePractice handles the administrative burden of running a private practice — eligibility verification, superbills, ERA processing — enabling clinicians to spend more time with clients and less time on paperwork. The company serves over 185,000 practitioners across the United States and has become the dominant practice management platform in the mental health private practice segment. Founded in 2012, SimplePractice raised over $50M from investors including Susquehanna Growth Equity and has grown organically through referrals within the therapist community. It competes with TherapyNotes, TheraNest, and Therapy Brands in the mental health software market.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.